We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Test for Sepsis-Related Pathogens Being Developed

By LabMedica International staff writers
Posted on 20 Oct 2009
A rapid assay for sepsis-related pathogens will provide results in less than two hours. More...
The fast access to information will enable physicians to quickly prescribe a specific course of treatment, thereby improving patient outcomes.

Smiths Detection (Watford, UK) received a $1 million, two-year grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB; Bethesda, MD, USA) to develop a rapid test for eight microorganisms that commonly cause burn/wound infections leading to septicemia (blood-poisoning).

The test will run on Smiths Detection's clinical Bio-Seeq system, designed to be used at point of care (POC) in critical care settings. With Bio-Seeq, the sample is introduced into a disposable cartridge, which is then placed on the instrument. The system should require no specialized molecular biology training.

Development of the highly multiplexed test will be achieved by using Smiths Detection's linear-after-the-exponential-polymerase chain reaction (LATE-PCR) nucleic acid amplification and detection technology. This technology was licensed from Brandeis University (Waltham, MA, USA), which will also support the project. The test will be suitable for use in a conventional laboratory setting or in a Point-of-Care (POC) setting running on the Bio-Seeq instrument.

Over 750,000 Americans develop sepsis each year. Globally, sepsis affects millions of people and is the leading cause of death in noncoronary Intensive Care Units (ICUs). Patients with more than 20% burn coverage, run a 97% risk of developing a wound infection, and the longer it takes to identify the cause, the higher the risk of full sepsis.

Traditional pathogen detection methods can take up to 72 hours and rapid molecular tests, when performed in a central laboratory, can take up to a day, depending on sample transport and processing times. Validation of the assay under development as well as evaluation of the performance of Bio-Seeq in an ICU setting will be conducted at the University of California (UC) Davis Medical Center (Sacramento, CA, USA).

Smiths Detection diagnostics unit is part of Smiths Group. It develops hardy instruments that are easily operated by specialists in clinical and veterinary procedures.

Related Links:
Smiths Detection
National Institute of Biomedical Imaging and Bioengineering
Brandeis University
University of California Davis Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.